IntegriChain delivers the life science industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, managed services and expert advisors to power their operations and harness the value of their channel, patient and payer data.
View all products
To ensure you get the most out of your access and commercialization investment, IntegriChain provides a complete set of professional Advisory and Systems Integration Services designed to further your business and success.
Services overview
IntegriChain provides wide array of resources to help you navigate your journey to market access success.
Resources overview
We help all stakeholders in the life sciences industry drive access. We do this through our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts and pricing, gross-to-net, channel, and patient services – unlocking strategic payer, provider, pharmacy and patient access insights for our life sciences customers.
Learn more about our company
Keep in touch with IntegrChain through our news and frequent events.
View all news & events
August 11, 2020 | 1:00 pm ET
On June 17, 2020, The Centers for Medicare & Medicaid Services (CMS) posted a proposed rule that could impact manufacturers’ Medicaid and 340B liabilities, commercial strategies, and patient assistance programs. At a high level, this proposed rule may:
In this webinar, we will attempt to demystify the potential impact the proposed rule may have on a participating manufacturer’s business. We will share insights and perspectives from the multitude of discussions we have had with manufacturers since the proposed rule was released and highlight some of the key questions that the proposed rule raises. We will also walk through several “real world” examples of how some of these proposed changes may impact a manufacturer’s business to explore the potential application of the more impactful aspects of the proposed rule.
Please join Rupal Patel, Director, Advisory Services and Carmela Crimeni, Director, Advisory Services.
Rupal Patel Carmela Crimeni
Register now!